Publications by authors named "Minal Barve"

Claim this Profile
P
Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study.
Nirav N Shah, Pier Luigi Zinzani, Michael Wang, Sunita D Nasta, Ewa Lech-Maranda, Minal A Barve

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies.
Daruka Mahadevan, Minal Barve, Devalingam Mahalingam, Jay Parekh, Michael Kurman

J Hematol Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Advanced Melanoma.
Antoni Ribas, Mohammed M Milhem, Christopher J Hoimes, Asim Amin, Christopher D Lao, Minal Barve

Clin Cancer Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With Alterations: A Phase Ia Dose-Escalation Study.
John V Heymach, Frans Opdam, Minal Barve, Hai-Yan Tu, Yi-Long Wu

J Clin Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer.
Oladapo O Yeku, Minal Barve, Winston W Tan, Judy Wang, Amita Patnaik

J Immunother Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.
Nirav N Shah, Michael Wang, Lindsey E Roeker, Krish Patel, Jennifer A Woyach, Minal A Barve

Haematologica· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial.
Herui Yao, Min Yan, Zhongsheng Tong, Xinhong Wu, Min-Hee Ryu, Minal Barve

J Clin Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic study of capivasertib and the CYP3A4 substrate midazolam in patients with advanced solid tumors.
Claire Miller, Roberto Sommavilla, Cindy L O'Bryant, Minal Barve, Afshin Dowlati

Cancer Chemother Pharmacol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors.
Agostina Stradella, Melissa Johnson, Sanjay Goel, Haeseong Park, Nehal Lakhani, Minal Barve

Cancer Med· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer.
Rona Yaeger, Nataliya V Uboha, Meredith S Pelster, Tanios S Bekaii-Saab, Minal Barve

Cancer Discov· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study.
Joaquina C Baranda, Debbie Robbrecht, Ryan Sullivan, Bernard Doger, Armando Santoro, Minal Barve

Clin Transl Sci· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumors.
Anthony P Conley, Christina L Roland, Alberto Bessudo, Brian R Gastman, Victoria M Villaflor, Minal A Barve

Cancer Gene Ther· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors.
Gerald Falchook, Amita Patnaik, Debra L Richardson, R Donald Harvey, Manish R Sharma, Minal Barve

Clin Ther· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors.
Dejan Juric, Minal Barve, Ulka Vaishampayan, Desamparados Roda, Aitana Calvo

Cancer Med· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adagrasib in Advanced Solid Tumors Harboring a Mutation.
Tanios S Bekaii-Saab, Rona Yaeger, Alexander I Spira, Meredith S Pelster, Joshua K Sabari, Minal Barve

J Clin Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer.
David Pook, Daniel M Geynisman, Joan Carles, Filippo de Braud, Anthony M Joshua, Minal Barve

Clin Cancer Res· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors.
Johanna Bendell, Patricia LoRusso, Michael Overman, Anne M Noonan, Dong-Wan Kim, Minal Barve

Cancer Immunol Immunother· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Operational Metrics for the ELAINE 2 Study Combining a Traditional Approach With a Just-in-TIME Model.
Sibel Blau, Julio Antonio Peguero, Halle C F Moore, Ian Churchill Anderson, Minal A Barve

JCO Clin Cancer Inform· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practical Guidance for the Management of Adverse Events in Patients with KRASG12C-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib.
Jun Zhang, Melissa Johnson, Minal Barve, Lyudmila Bazhenova, Marybeth McCarthy

Oncologist· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations.
John Heymach, Frans Opdam, Minal Barve, Neil Gibson, Behbood Sadrolhefazi

Clin Lung Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumors.
Aung Naing, Alain P Algazi, Gerald S Falchook, Benjamin C Creelan, John Powderly, Minal Barve

Cancer· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated G12C.
Rona Yaeger, Jared Weiss, Meredith S Pelster, Alexander I Spira, Minal Barve

N Engl J Med· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors.
Santosh Kesari, Alberto Bessudo, Brian R Gastman, Anthony P Conley, Victoria M Villaflor, Minal A Barve

Future Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors (KRYSTAL-1).
Sai-Hong Ignatius Ou, Pasi A Jänne, Ticiana A Leal, Igor I Rybkin, Joshua K Sabari, Minal A Barve

J Clin Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer.
Minal Barve, Phylicia Aaron, Luisa Manning, Ernest Bognar, Gladice Wallraven

Clin Med Insights Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis